Trial Profile

A Randomised Phase II Trial of Oral Vinorelbine as Second Line Therapy for Patients With Malignant Pleural Mesothelioma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vinorelbine (Primary)
Indications Malignant-mesothelioma
Focus Therapeutic Use
Acronyms VIM

Most Recent Events

04 Oct 2021 Status changed from active, no longer recruiting to completed.
08 Jun 2021 Primary endpoint has been met (Progression free survival; defined as the time from randomisation to any progression , according to Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com